Generalized estimating equation regression analysis, where final blood level of CBD was included as an explanatory variable and for which there were 26 patients receiving CBD and 27 patients receiving placebo with data, revealed that CBD treatment trended toward reducing the presence of SD compared with the placebo ( P =.07 at the mean CBD final blood level of 49.29 ng/mL) because there was an estimated improvement for the CBD group and an estimated worsening for the placebo group, but this finding did not reach statistical significance.
← all excerpts
Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial.
1
—
—